Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018

GlobalData, September 2011, Pages: 75

Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Post-Menopausal Hormone Replacement Therapy (HRT) market. The report identifies the key trends shaping and driving the global Post-Menopausal Hormone Replacement Therapy (HRT) market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Post-Menopausal Hormone Replacement Therapy (HRT) sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Post-Menopausal Hormone Replacement Therapy (HRT) market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Post-Menopausal Hormone Replacement Therapy (HRT) market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Post-Menopausal Hormone Replacement Therapy (HRT) market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Post-Menopausal Hormone Replacement Therapy (HRT) market.
- Analysis of key recent licensing and partnership agreements in Post-Menopausal Hormone Replacement Therapy (HRT) market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Post-Menopausal Hormone Replacement Therapy (HRT) market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Post-Menopausal Hormone Replacement Therapy (HRT) market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Post-Menopausal Hormone Replacement Therapy (HRT) market landscape? – Identify, understand and capitalize.

1 Table of contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Post- Menopause Therapeutics - Introduction
2.1 Overview
2.2 Epidemiology
2.2.1 Prevalence
2.2.2 Morbidity
2.2.3 Mortality
2.2.4 Quality of life
2.2.5 Pharmaco-economic Burden
2.3 Physiology
2.4 Signs and Symptoms
2.4.1 Vasomotor Symptoms
2.4.2 Neuropsychiatric Symptoms
2.4.3 Associated States
2.4.4 Other
2.5 Diagnosis
2.5.1 FSH Blood Level Measurement
2.5.2 Estrogen Levels
2.5.3 Other Ovarian Hormones
2.6 Treatment and Management Options
2.6.1 Post-menopausal HRT
2.6.2 Types of Post-Menopausal HRT
2.6.3 Management of Menopause-Related Symptoms with Post-Menopausal HRT
2.6.4 Side Effects of Post-Menopausal HRT
2.6.5 Risks Associated with Post-Menopausal HRT
2.7 Referral Pathway
2.8 Pipeline Report Guidance
3 Post- Menopausal HRT - Market Characterization
3.1 Overview
3.2 Post-Menopausal HRT Market Size (2005–2010) – Global
3.3 Post-Menopausal HRT Market Forecast (2010–2018) – Global
3.4 Post-Menopausal HRT Market Size (2005–2010) – The US
3.5 Post-Menopausal HRT Market Forecast (2010–2018) – The US
3.6 Post-Menopausal HRT Market Size (2005–2010) – France
3.7 Post-Menopausal HRT Market Forecast (2010–2018) – France
3.8 Post-Menopausal HRT Market Size (2005–2010) – Germany
3.9 Post-Menopausal HRT Market Forecast (2010–2018) – Germany
3.10 Post-Menopausal HRT Market Size (2005–2010) – Italy
3.11 Post-Menopausal HRT Market Forecast (2010–2018) – Italy
3.12 Post-Menopausal HRT Market Size (2005–2010) – Spain
3.13 Post-Menopausal HRT Market Forecast (2010–2018) – Spain
3.14 Post-Menopausal HRT Market Size (2005–2010) – The UK
3.15 Post-Menopausal HRT Market Forecast (2010–2018) – The UK
3.16 Post-Menopausal HRT Market Size (2005–2010) – Japan
3.17 Post-Menopausal HRT Market Forecast (2010–2018) – Japan
3.18 Drivers and Barriers for the Post-Menopausal HRT Market
3.18.1 Drivers for the Post-Menopausal HRT Market
3.18.2 Restraints for the Post-Menopausal HRT Market
3.19 Opportunity and Unmet Need Analysis
3.20 Key Takeaway
4 Post- Menopausal HRT - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Post-Menopausal HRT Market
4.3.1 Premarin (Conjugated estrogens)
4.3.2 Vagifem (estradiol vaginal tablets)
4.3.3 Femring (estradiol acetate vaginal ring)
4.3.4 Prempro (Conjugated estrogens/medroxyprogesterone acetate tablets)
4.4 Key Takeaway
5 Post- Menopausal HRT - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Post-Menopausal HRT Pipeline – Pipeline by Phases of Development
5.3.1 Post-Menopausal HRT – Phase III Pipeline
5.3.2 Post-Menopausal HRT – Phase II Pipeline
5.3.3 Post-Menopausal HRT – Pre-Clinical Pipeline
5.3.4 Technology Trends Analytic Framework
5.4 Post-Menopausal HRT Market –Pipeline by Mechanism of Action
5.5 Post-Menopausal HRT – Promising Drugs under Clinical Development
5.6 Molecule Profile for Promising Drugs under Clinical Development
5.6.1 Aprela (Bazedoxifene/conjugated estrogen)
5.6.2 Vaginorm (0.5% Dehydroepiandrosterone)
5.7 Key Takeaway
6 Post- Menopausal HRT - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Post-Menopausal HRT Clinical Trials
7 Post- Menopausal HRT - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Post-Menopausal HRT: Implications for Future Market Competition
8 Post- Menopausal HRT - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Pfizer Inc.
8.2.2 Bayer AG
8.2.3 Paladin Labs, Inc.
8.3 Other Companies in Post-Menopausal HRT Therapeutics Market
9 Post-Menopausal HRT - Licensing and Partnership Deals
10 Post- Menopausal HRT - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Effects of Oral HRT on Annual Incidence of Selected Disorders in Post-Menopausal Women
Table 2: Mortality by Post-Menopausal HRT Use
Table 3: FSH Blood Level Measurement
Table 4: Estrogen Blood Level Measurement
Table 5: Treatment and Management Options in Post-Menopause
Table 6: Post-Menopausal HRT Market, Global, Revenue ($m), 2005–2010
Table 7: Post-Menopausal HRT Market, Global, Forecast ($m), 2010–2018
Table 8: Post-Menopausal HRT Market, The US, Revenue ($m), 2005–2010
Table 9: Post-Menopausal HRT Market, The US, Forecasts ($m), 2010–2018
Table 10: Post-Menopausal HRT Market, France, Revenue ($m), 2005–2010
Table 11: Post-Menopausal HRT Market, France, Forecasts ($m), 2010–2018
Table 12: Post-Menopausal HRT Market, Italy, Revenue ($m), 2005–2010
Table 13: Post-Menopausal HRT Market, Germany, Forecasts ($m), 2010–2018
Table 14: Post-Menopausal HRT Market, Italy, Revenue ($m), 2005–2010
Table 15: Post-Menopausal HRT Market, Italy, Forecasts ($m), 2010–2018
Table 16: Post-Menopausal HRT Market, Spain, Revenue ($m), 2005–2010
Table 17: Post-Menopausal HRT Market, Spain, Forecasts ($m), 2010–2018
Table 18: Post-Menopausal HRT Market, the UK, Revenue ($m), 2005–2010
Table 19: Post-Menopausal HRT Market, the UK, Forecasts ($m), 2010–2018
Table 20: Post-Menopausal HRT Market, Japan, Revenue ($m), 2005–2010
Table 21: Post-Menopausal HRT Market, Japan, Forecasts ($m), 2010–2018
Table 22: Percentage Treatment-Emergent Adverse Events Reported in Women Receiving Premarin
Table 23: Mean Values and Comparisons between Active Treatment Groups and the Placebo Group for the Number of Flashes per Day
Table 24: Percentage Treatment-Emergent Adverse Events Reported in Women Receiving Vagifem
Table 25: Mean Change from Baseline to Week 12 in a Composite Score of Most Irritating Symptoms Compared to Placebo
Table 26: Percentage Treatment-Emergent Adverse Events Reported in Women Receiving Femring
Table 27: Mean Change from Baseline in the Number of Moderate to Severe Vasomotor Symptoms per Week
Table 28: Percentage Treatment-Emergent Adverse Events Reported in Women Receiving Prempro
Table 29: Mean Values and Comparisons between the Active Treatment Groups and the Placebo Group for the Number of Flashes per Day
Table 30: Post-Menopausal HRT, Phase III Pipeline, 2011
Table 31: Post-Menopausal HRT, Phase II Pipeline, 2011
Table 32: Post-Menopausal HRT , Pre-Clinical Pipeline, 2011
Table 33: Post-Menopausal HRT – Most Promising Drugs Under Clinical Development, 2011
Table 34: Post-Menopausal HRT, Clinical Trials by Country, 2011
Table 35: Post-Menopausal HRT - Clinical Trials by Phase, 2011
Table 36: Post-Menopausal HRT, Clinical Trials by Status (%), 2011
Table 37: Post-Menopausal HRT, Prominent Sponsors, 2011
Table 38: Post-Menopausal HRT, Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 39: Pfizer Inc., Menopause Management, Pipeline, 2011
Table 40: Bayer AG, Menopausal Management, Pipeline, 2011
Table 41: Paladin Labs Inc., Menopausal Management, Pipeline, 2011
Table 42: Post-Menopausal HRT Market – Future Players, 2011
Table 43: Post-Menopausal HRT, Global, Deals, 2009-2011

1.2 List of Figures
Figure 1: The Stages of Reproductive Aging Workshop (STRAW)
Figure 2: Estradiol and FSH Levels During a Normal Menstrual Cycle and Menopause
Figure 3: Sign and Symptoms of Post-Menopause
Figure 4: Treatment Algorithm for Post-Menopausal HRT-
Figure 5: Side Effects of Post-Menopausal HRT
Figure 6: Referral Pathway
Figure 7: Post-Menopausal HRT Market, Global, Revenue ($m), 2005–2010
Figure 8: Post-Menopausal HRT Market, Global, Forecast ($m), 2010–2018
Figure 9: Post-Menopausal HRT Market, The US, Revenue ($m), 2005–2010
Figure 10: Post-Menopausal HRT Market, The US, Forecast ($m), 2010–2018
Figure 11: Post-Menopausal HRT Market, France, Revenue ($m), 2005–2010
Figure 12: Post-Menopausal HRT Market, France, Forecast ($m), 2010–2018
Figure 13: Post-Menopausal HRT Market, Germany, Revenue ($m), 2005–2010
Figure 14: Post-Menopausal HRT Market, Germany, Forecast ($m), 2010–2018
Figure 15: Post-Menopausal HRT Market, Italy, Revenue ($m), 2005–2010
Figure 16: Post-Menopausal HRT Market, Italy, Forecast ($m), 2010–2018
Figure 17: Post-Menopausal HRT Market, Spain, Revenue ($m), 2005–2010
Figure 18: Post-Menopausal HRT Market, Spain, Forecast ($m), 2010–2018
Figure 19: Post-Menopausal HRT Market, the UK, Revenue ($m), 2005–2010
Figure 20: Post-Menopausal HRT Market, the UK, Forecast ($m), 2010–2018
Figure 21: Post-Menopausal HRT Market, Japan, Revenue ($m), 2005–2010
Figure 22: Post-Menopausal HRT Market, Japan, Forecast ($m), 2010–2018
Figure 23: Opportunity and Unmet Need in the Post-Menopausal HRT Market, 2010
Figure 24: Post-Menopausal HRT, Strategic Competitor Assessment, 2010
Figure 25: Post-Menopausal HRT – Pipeline by Phase of Development, 2011
Figure 26: Post-Menopausal HRT, Technology Trends Analytics Framework, 2011
Figure 27: Post-Menopausal HRT, Technology Trends Analytics Framework, Description, 2011
Figure 28: Post-Menopausal HRT, Pipeline by Mechanism of Action (%), 2011
Figure 29: Molecular Structure of Dehydroepiandrosterone (DHEA)
Figure 30: Post-Menopausal HRT, Clinical Trials by Country, 2011
Figure 31: Post-Menopausal HRT, Clinical Trials by Phase (%), 2011
Figure 32: Post-Menopausal HRT, Clinical Trials by Status (%), 2011
Figure 33: Post-Menopausal HRT, Overall Sponsors (%), 2011
Figure 34: Post-Menopausal HRT, Prominent Sponsors (%), 2011
Figure 35: Post-Menopausal HRT, Top Companies Participating in Clinical Trials, 2011
Figure 36: Post-Menopausal HRT Market, Drivers and Restraints, 2011
Figure 37: Post-Menopausal HRT, Implications for Future Market Competition, 2011
Figure 38: Post-Menopausal HRT Market, Pipeline by Company, 2011
Figure 39: Market Forecasting Model

Pfizer Inc.
Bayer AG
Paladin Labs, Inc

Customers who bought this item also bought

• Hormone Replacement Therapy (HRT) - Global Strategic Business Report
• Global Menopausal Syndrome Drug Pipeline Capsule - 2012
• Pipeline and Commercial Insight: Hormonal Replacement Therapy for Menopausal Symptoms - Safety fears continue to haunt the market
• Medical Nutrition - A Global Market Overview
• Disinfectants - Global Strategic Business Report
• Mammography Equipment - Global Strategic Business Report
• Diabetes Diagnostics - Global Strategic Business Report
• Women’s Health in Food and Drinks: Future Functional Ingredients and Innovations
• Clinical Diagnostics Automation - Global Business Strategic Report
• Wheelchairs (Powered and Manual) - Global Strategic Business Report